NCT04161456View on ClinicalTrials.gov

Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

February 8, 2021

Study Completion Date

February 8, 2021

Conditions
Acne Conglobata
Interventions
DRUG

Apremilast

Apremilast twice daily 30 mg

Trial Locations (1)

60590

University Hospital Frankfurt, Frankfurt

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Dermatology Department University Hospital Frankfurt

UNKNOWN

collaborator

Celgene

INDUSTRY

lead

Dr. Frank Behrens

OTHER

NCT04161456 - Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata | Biotech Hunter | Biotech Hunter